Evidence map›Paper›PMID 35960734›Full record

ArticlePloS one2022

Optimal dose of lactoferrin reduces the resilience of in vitro Staphylococcus aureus colonies.

Jagir R Hussan, Stuart G Irwin, Brya Mathews, Simon Swift, Dustin L Williams, Jillian Cornish

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jagir R HussanAuckland Bioengineering Institute, University of Auckland, Auckland, NZ.ORCID 0000-0002-8333-7869
Stuart G IrwinDepartment of Molecular Medicine and Pathology, University of Auckland, Auckland, NZ.
Brya MathewsDepartment of Molecular Medicine and Pathology, University of Auckland, Auckland, NZ.
Simon SwiftDepartment of Molecular Medicine and Pathology, University of Auckland, Auckland, NZ.
Dustin L WilliamsDepartment of Microbiology and Immunology, School of Medicine, University of Utah, Salt Lake City, Utah, United States of America.
Jillian CornishDepartment of Medicine, University of Auckland, Auckland, NZ.
University of Auckland · NZUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rise in antibiotic resistance has stimulated research into adjuvants that can improve the efficacy of broad-spectrum antibiotics. Lactoferrin is a candidate adjuvant; it is a multifunctional iron-binding protein with antimicrobial properties. It is known to show dose-dependent antimicrobial activity against Staphylococcus aureus through iron sequestration and repression of β-lactamase expression. However, S. aureus can extract iron from lactoferrin through siderophores for their growth, which confounds the resolution of lactoferrin's method of action. We measured the minimum inhibitory concentration (MIC) for a range of lactoferrin/ β-lactam antibiotic dose combinations and observed that at low doses (< 0.39 μM), lactoferrin contributes to increased S. aureus growth, but at higher doses (> 6.25 μM), iron-depleted native lactoferrin reduced bacterial growth and reduced the MIC of the β-lactam-antibiotic cefazolin. This differential behaviour points to a bacterial population response to the lactoferrin/ β-lactam dose combination. Here, with the aid of a mathematical model, we show that lactoferrin stratifies the bacterial population, and the resulting population heterogeneity is at the basis of the dose dependent response seen. Further, lactoferrin disables a sub-population from β-lactam-induced production of β-lactamase, which when sufficiently large reduces the population's ability to recover after being treated by an antibiotic. Our analysis shows that an optimal dose of lactoferrin acts as a suitable adjuvant to eliminate S. aureus colonies using β-lactams, but sub-inhibitory doses of lactoferrin reduces the efficacy of β-lactams.

Indexed as

Staphylococcal InfectionsStaphylococcus aureusAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsHumansIronLactoferrinMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsIronLactoferrin

Identifiers

PMID35960734
PMCPMC9374217
OpenAlexW4290851951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.